Johnson & Johnson $JNJ Stock Holdings Boosted by Ninety One UK Ltd

Key Points

• Ninety One UK Ltd increased its holdings in Johnson & Johnson by 1.3% during the 2nd quarter, now owning over 7 million shares valued at approximately $1.07 billion.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, yielding approximately 2.8%, with a dividend payout ratio of 55.61%.
• Shares of Johnson & Johnson are currently trading around $185.98, with a market cap of $447.91 billion and analysts projecting a fiscal year EPS of 10.58.

Ninety One UK Ltd grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,016,164 shares of the company's stock after purchasing an additional 93,119 shares during the period. Johnson & Johnson comprises about 2.5% of Ninety One UK Ltd's portfolio, making the stock its 10th largest position. Ninety One UK Ltd owned about 0.29% of Johnson & Johnson worth $1,071,719,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Apexium Financial LP raised its position in Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after acquiring an additional 2,310 shares during the period. Avanza Fonder AB lifted its stake in Johnson & Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock valued at $35,842,000 after purchasing an additional 6,566 shares during the last quarter. Joel Isaacson & Co. LLC grew its stake in shares of Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after acquiring an additional 2,526 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its stake in Johnson & Johnson by 7.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after acquiring an additional 4,816 shares during the period. Finally, Range Financial Group LLC lifted its holdings in Johnson & Johnson by 18.9% during the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after purchasing an additional 2,529 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $185.98 on Friday. The stock's 50-day simple moving average is $175.78 and its two-hundred day simple moving average is $162.66. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $186.59. The firm has a market capitalization of $447.91 billion, a P/E ratio of 19.89, a P/E/G ratio of 2.37 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson's revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on JNJ. Bank of America lifted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Morgan Stanley boosted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Guggenheim raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. UBS Group lifted their target price on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Finally, Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $181.40.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.